Sanofi

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

Thursday, October 21, 2021 - 2:00pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.
  • BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles.
  • Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.
  • Ligands OmniAb technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies.

Neeyamo's Focus on Technology and Innovation Makes It a Potential Leader in the Fosway 9-Grid™ for Cloud HR Solutions

Monday, October 18, 2021 - 3:22pm

According to Fosway, a potential leader provides sophisticated solutions with comprehensive suites of capabilities that are well suited to complex organizations.

Key Points: 
  • According to Fosway, a potential leader provides sophisticated solutions with comprehensive suites of capabilities that are well suited to complex organizations.
  • The Fosway 9-Grid is a unique, five-dimensional market analysis model that helps HR buyers demystify supplier decisions for incorporating next-gen HR, Talent, and Learning.
  • "We are happy to have made progress in further consolidating our position as a Potential Leader in Fosway Group's 9-Grid for Cloud HR.
  • "Neeyamo has consolidated its position as a Potential Leader by consistently delivering innovation for organizations that operate across a wide range of geographies."

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Thursday, October 14, 2021 - 3:45pm

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

Tentarix Biotherapeutics Emerges with $50 Million Series A

Thursday, October 14, 2021 - 2:00pm

Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.

Key Points: 
  • Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.
  • This financing allows us to develop multiple programs for oncology and autoimmune disease based on the Tentarix technology platform.
  • The company's proprietary platform facilitates high throughput discovery and optimization of biotherapeutics with high cell selectivity, differentiated functionality, and robust mammalian expression that enables molecular developability.
  • Tentarix is advancing programs in many other fields including cell type specific reprogramming and cell population specific delivery and internalization.

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Thursday, October 14, 2021 - 12:00pm

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today.

Key Points: 
  • ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today.
  • His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.
  • Prior to CRISPR Therapeutics, Mr. Smith was the Chief Financial Officer & Corporate Strategy of Translate Bio, a leading mRNA company that was recently acquired by Sanofi for $3.2B.
  • CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG.

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

Wednesday, October 13, 2021 - 12:00pm

A Keynote Plenary Session presentation will include safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers that has recently completed dose escalation.

Key Points: 
  • A Keynote Plenary Session presentation will include safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers that has recently completed dose escalation.
  • We look forward to presenting PK and PD data, including IRAK4 levels and cytokine results, from the SAD portion of the KT-474 Phase 1 randomized, placebo-controlled trial in healthy volunteers.
  • Additionally, while we have completed Single Ascending Dose escalation, the Multiple Ascending Dose (MAD) portion of the trial continues in healthy volunteers.
  • We plan to present data from the MAD portion of our healthy volunteer Phase 1 study before year-end.

New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma

Wednesday, October 13, 2021 - 11:10am

Every patient is unique, and this new indication means SARCLISA has the potential to benefit a wide variety of Canadians living with multiple myeloma."

Key Points: 
  • Every patient is unique, and this new indication means SARCLISA has the potential to benefit a wide variety of Canadians living with multiple myeloma."
  • This approval marks the second indication for SARCLISA in combination with a standard of care regimen for the treatment of relapsed and/or refractory MM.
  • Previously, SARCLISA received Health Canada approval in combination with another standard of care regimen, pomalidomide and dexamethasone (Pd), for the treatment of adult patients with relapsed and refractory MM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
  • These findings strengthen our confidence in isatuximab in the relapsed and refractory setting and demonstrate that isatuximab is becoming a standard of care in this environment."

Online Reputation Management Focus of Beverly Hills Bar Association Interview with Reputation Communications CEO Shannon Wilkinson

Monday, October 11, 2021 - 1:41pm

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- In a new interview with the Beverly Hills Bar Association , Reputation Communications Founder and CEO Shannon Wilkinson explains reputation management and expert reputation witness work and highlights the need for individuals and business to protect their reputations as they do any other asset.

Key Points: 
  • NEW YORK, Oct. 11, 2021 /PRNewswire/ -- In a new interview with the Beverly Hills Bar Association , Reputation Communications Founder and CEO Shannon Wilkinson explains reputation management and expert reputation witness work and highlights the need for individuals and business to protect their reputations as they do any other asset.
  • "Online reputation management exists because you are who Google says you are," Wilkinson explains.
  • Shannon M. Wilkinson is a nationally recognized expert in digital reputation management and an expert witness for legal cases related to reputation issues.
  • Founded in 2009, Reputation Communications was one of the first companies to specialize in online reputation management.

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

Thursday, October 7, 2021 - 12:25pm

LAUSANNE, Switzerland, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oculis S.A., (Oculis) a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Dr. Joanne Chang, M.D., Ph.D., as Chief Medical Officer and Head of Portfolio Management. Dr. Chang brings unique R&D and medical affairs expertise given her experience in multiple geographies (U.S., China and globally), as well as a deep portfolio expertise in Ophthalmology covering all key areas such as cornea, retina, and gene therapy.

Key Points: 
  • Oculis also announces the opening of a new office in Hong Kong to broaden the companys development and commercial capabilities in Greater China and Asia, a strategically important region.
  • Dr. Chang will be based in the Hong Kong office and will have global responsibility for Medical Affairs and Corporate Portfolio Management.
  • Joanne brings global industry and operational expertise as well as strong leadership, which will be key as our late-stage product candidates start their Phase 3 trials.
  • Dr. Chang brings to Oculis more than 20 years of global experience in medical and regulatory affairs, clinical development, health economics and market access.

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)

Wednesday, October 6, 2021 - 9:01pm

DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.

Key Points: 
  • DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.
  • Denali presented positive results from a Phase 1 study in healthy volunteers (n=95) in which safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of DNL343 were evaluated.
  • Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.